<DOC>
	<DOC>NCT00986778</DOC>
	<brief_summary>Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in Chinese adults with lamivudine-resistant chronic hepatitis B infection</brief_summary>
	<brief_title>Entecavir Plus Adefovir in Lamivudine-Resistant Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>CHB HBeAg(+) Subject with Lamivudine treatment history must have LVDr substitution at rtM204V/I Naïve to nucleoside/nucleotide analogues except for LVD HBV DNA &gt; 17,200 IU/mL Compensated liver function Serum ALT &lt;10 × ULN Women who are pregnant or breastfeeding Evidence of decompensated cirrhosis Coinfection with HIV, hepatitis C virus (HCV), or hepatitis D virus (HDV)</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>